Skye Bioscience Shareholders Alerted to Important Class Action Lawsuit Details

Attention Skye Bioscience Shareholders

On January 5, 2026, The Gross Law Firm released a crucial notification aimed at shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE). This announcement is essential for those who have acquired shares between November 4, 2024, and October 3, 2025. The firm indicates that these shareholders may have standing to join a class action lawsuit stemming from alleged misleading statements made by the company's management regarding their lead product candidate, nimacimab.

Understanding the Class Action Lawsuit

The lawsuit claims that during the specified class period, Skye Bioscience's management knowingly provided inaccurate representations about nimacimab’s effectiveness. It is alleged that management overstated its clinical, regulatory, and commercial prospects, thus misguiding investors into believing that the product was performing better than it actually was. This situation is of considerable concern, as the claims put forward suggest that investors could potentially be facing significant losses based on these misleading assurances.

Important Deadlines

Shareholders should pay particular attention to the deadline of January 16, 2026, for registering as participants in the class action. Failing to act promptly could mean missing out on the opportunity for recovery, should the court find in favor of shareholders. The Gross Law Firm emphasizes that even those who do not wish to be appointed as lead plaintiffs can still partake in the recovery process if they register their information within the stipulated timeframe.

What Actions to Take

Shareholders are urged to visit the law firm's dedicated page to register their interest and enable tracking of updates pertaining to the lawsuit. Through the registration process, shareholders will be integrated into a portfolio monitoring system that keeps them informed throughout the case lifecycle. This service comes at no cost, which allows affected investors to stay active and aware of any developments regarding their interests.

The Role of The Gross Law Firm

The Gross Law Firm has established itself as a highly regarded entity in securities litigation, dedicated to the protection of investors' rights against fraud and corporate wrongdoing. They are committed to pursuing recovery on behalf of those adversely affected by deceptive business practices. The firm encapsulates a strong belief that ethical conduct should guide all corporate entities and strives to hold companies accountable when misconduct occurs. This principle is particularly critical in cases like that of Skye Bioscience, where investor trust has been undermined.

For those wanting more information, they can reach out to The Gross Law Firm at their New York office, or utilize their secure email and phone contact methods for inquiries and advice.

Conclusion

This is a vital moment for shareholders of Skye Bioscience, Inc. Immediate registration and participation in the class action suit are recommended to protect potential losses. With ongoing developments likely, keeping a close watch on this situation through the provided channels will help safeguard shareholder interests moving forward. Shareholders are strongly encouraged to act now, ensuring that they are adequately represented and informed during this crucial legal battle.